SCHEDULE: Baker Bros. Boosts Acadia Stake, Secures Resale Rights

Baker Bros. Advisors and its affiliates have updated their significant beneficial ownership in ACADIA Pharmaceuticals Inc. and secured new registration rights for their securities.

Summary

• Baker Bros. Advisors LP and its affiliates, including Julian C. Baker and Felix J. Baker, collectively beneficially own approximately 25.3% to 25.4% of ACADIA Pharmaceuticals Inc.'s common stock.
• This beneficial ownership is based on 170,494,613 shares of Common Stock outstanding as of February 18, 2026.
• The holdings include common stock, vested and unvested stock options, restricted stock units (RSUs), and prefunded warrants.
• Julian C. Baker and Dr. Stephen R. Biggar, serving on ACADIA's Board, hold stock options and RSUs as compensation, with the pecuniary interest belonging to the Funds managed by Baker Bros.
• Prefunded Warrants, exercisable at $0.01 per share, are subject to a 19.99% beneficial ownership limitation and are currently not exercisable due to this restriction.
• A new Registration Rights Agreement was entered into on February 24, 2026, granting the Funds certain resale registration rights for their securities, including the right to request underwritten public offerings.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, primarily due to the establishment of a clear, long-term liquidity strategy for a major institutional investor, which can be seen as a sign of continued commitment and strategic planning, despite the current non-exercisability of warrants.

Positives

• The new Registration Rights Agreement provides Baker Bros. Funds with enhanced flexibility to monetize their significant holdings in ACADIA Pharmaceuticals Inc. through public offerings or block trades.
• The agreement allows for up to three underwritten public offerings in total and two per twelve-month period, providing clear pathways for potential future liquidity.
• The continued significant beneficial ownership by Baker Bros. (over 25%) indicates a strong, long-term conviction in ACADIA Pharmaceuticals Inc.

Negatives

• Prefunded Warrants, which allow for acquisition of common stock at a low exercise price of $0.01, are currently not exercisable due to a 19.99% beneficial ownership limitation.
• The inability to exercise these warrants immediately restricts the Funds from increasing their direct common stock holdings via this mechanism.

Risks

• The Beneficial Ownership Limitation of 19.99% on Prefunded Warrants prevents immediate exercise, potentially limiting the Funds' ability to fully capitalize on their warrant holdings if they wish to increase their stake beyond this threshold.
• The effectiveness of increasing the Beneficial Ownership Limitation requires a 65-day notice period, introducing a delay in strategic adjustments.
• The value of the Prefunded Warrants is dependent on the market price of ACADIA's common stock and the ability to exercise them, which is currently restricted.

Future Outlook

The newly established Registration Rights Agreement provides a clear framework for Baker Bros. to potentially divest portions of its significant stake in ACADIA Pharmaceuticals Inc. over the next ten years through various public offering mechanisms, signaling a long-term, yet flexible, investment strategy.

Management Comments

• The Funds' respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds' investments and voting power over investments.
• The policy of the Funds and the Adviser does not permit managing members of the Adviser GP or full-time employees of the Adviser to receive compensation for serving as directors of the Issuer, and the Funds are instead entitled to the pecuniary interest in the Stock Options, RSUs and common stock received from the exercise of Stock Options or vesting of RSUs.
• Julian C. Baker and Dr. Biggar have no voting or dispositive power and no pecuniary interest in the Stock Options, RSUs and Common Stock received from the exercise of Stock Options or vesting of RSUs.

Industry Context

StockSavvy.ai notes that significant institutional investor filings like this Schedule 13D/A are closely watched in the biotechnology and pharmaceutical sectors. Baker Bros. Advisors is a prominent life sciences investor, and their continued substantial stake, coupled with securing registration rights, suggests a strategic long-term position in ACADIA. This move is typical for large, long-term holders seeking to maintain liquidity options for their substantial investments, especially in a sector where company valuations can fluctuate significantly based on clinical trial results and regulatory approvals.

Comparison to Industry Standards

• Securing registration rights is a standard practice for large institutional investors, such as Baker Bros., when they hold a significant, illiquid stake in a public company. This allows them to exit positions without disrupting the market, similar to how other major biotech investors like Orbimed or RA Capital Management might negotiate such terms.
• For instance, when Fidelity or BlackRock hold substantial positions in companies like Amgen or Gilead Sciences, they often have similar agreements to facilitate orderly sales.
• The 19.99% beneficial ownership limitation on warrant exercise is also a common anti-takeover or regulatory compliance measure seen in many investment agreements to avoid triggering certain reporting or control thresholds.

Corporate Governance

Related Party Transactions

• Julian C. Baker and Dr. Stephen R. Biggar, who serve on the Board of Directors of ACADIA Pharmaceuticals Inc. as representatives of the Funds, receive Stock Options, restricted stock units (RSUs), and Common Stock as compensation.
• The pecuniary interest in these Stock Options, RSUs, and Common Stock belongs to the Funds, not to Julian C. Baker or Dr. Biggar personally, aligning their compensation with the Funds' investment.
• Julian C. Baker and Felix J. Baker directly hold 102,876 shares of Common Stock and 1,569 Prefunded Warrants each, received from in-kind pro rata distributions without consideration.
• FBB3 LLC, managed by Julian C. Baker and Felix J. Baker, directly holds 734 Prefunded Warrants.

Stakeholder Impact

• Shareholders: The Registration Rights Agreement provides a mechanism for a large institutional investor to potentially sell shares, which could introduce supply to the market. However, it also signals a structured approach to managing a significant stake. The continued large ownership by Baker Bros. may be seen as a vote of confidence.
• Company Management: The agreement formalizes a process for managing a major shareholder's liquidity needs, requiring the company to facilitate registration statements.

Next Steps

• The Issuer is obligated to file a resale registration statement on Form S-3 or other appropriate form covering Registrable Securities held by the Funds following a request.
• The Issuer must use reasonable best efforts to keep the Resale Registration Shelf effective for up to ten years or until all Registrable Securities can be sold freely.
• The Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to their Prefunded Warrants by written notice to the Issuer, with any increase effective 65 days after notice.

Key Dates

Recommendation

The filing primarily details an update to beneficial ownership and the establishment of a registration rights agreement for a major institutional investor. While the registration rights provide a clear path for future liquidity, they do not indicate an immediate intent to sell, nor do they reflect new operational or financial performance data for ACADIA Pharmaceuticals Inc. The continued significant stake by Baker Bros. suggests ongoing confidence. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current position while monitoring future developments related to the company's performance and any potential sales by Baker Bros.

Keywords

ACADIA Pharmaceuticals, Baker Bros. Advisors, Schedule 13D, Beneficial Ownership, Registration Rights Agreement, Prefunded Warrants, Biotechnology, Pharmaceuticals, Institutional Investor, SEC Filing